21st week of 2013 patent applcation highlights part 45 |
Patent application number | Title | Published |
20130129684 | METHOD OF INHIBITING METHANOGENESIS - The object of the present invention is to provide a technique to inhibit methanogens from producing methane. The use of | 2013-05-23 |
20130129685 | Stabilisation of Viral Particles - A method for preserving viral particles comprising: (a) providing an aqueous solution of (i) viral particles, (ii) optionally one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating said viral particles. | 2013-05-23 |
20130129686 | Reducing Inflammation Using Cell Therapy - The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component, including graft-versus-host disease. The invention is generally directed to reducing inflammation by administering cells that express and/or secrete prostaglandin E2 (PGE2). The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete PGE2, such as PGE2 receptor agonists. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of PGE2 expression and/or secretion. The invention is also generally directed to delivering cells directly to lymphohematopoietic tissue, such as spleen, lymph nodes, and bone marrow. The invention is, thus, also directed to a method for treating inflammation by administering cells directly into sites of lymphohematopoiesis, such as spleen, lymph nodes, and bone marrow. The administered cells include those that reduce the activation and/or proliferation of T-cells. Such cells may or may not express and/or secrete PGE2. | 2013-05-23 |
20130129687 | Generation of Lineage-Restricted Progenitor Cells from Differentiated Cells - Method for reprogramming differentiated cells into lineage restricted progenitor cells is provided. The method may include contacting differentiated cells with inhibitors of tyrosine phosphatases and apoptosis to de-differentiate differentiated cells into lineage restricted progenitor cells. | 2013-05-23 |
20130129688 | Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same - The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stem cell (MSC) populations by determining the number of GT repeats in the heme oxygenase-1 (HO-1) promoter region of both alleles. | 2013-05-23 |
20130129689 | AGENT DERIVED FROM TORTOISE SPLEEN STIMULATING MAMMALIAN HEMOPOIESIS - The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them. | 2013-05-23 |
20130129690 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 2013-05-23 |
20130129691 | Compositions For The Treatment Of Skin Conditions, Disorders Or Diseases And Methods Of Making And Using The Same - The present invention includes methods and compositions designed for treating a subject suffering from a skin condition, disorder or disease. The compositions include undifferentiated fetal skin cells that are either integrated with a collagen matrix or a carrier. | 2013-05-23 |
20130129692 | PLURIPOTENT CELLS - Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration. | 2013-05-23 |
20130129693 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 2013-05-23 |
20130129694 | USE OF LIVE BACTERIA FOR GROWTH PROMOTION IN ANIMALS - The present invention relates to the use of F4 | 2013-05-23 |
20130129695 | METHODS FOR TREATING OR INHIBITING INFECTION BY CLOSTRIDIUM DIFFICILE - The invention provides methods for treating or inhibiting infection by | 2013-05-23 |
20130129696 | Human Stem Cell Materials and Methods - Monocyte derived adult stem cells (MDSCs) isolated from peripheral blood of mammals is provided, along with pharmaceutical compositions containing an MDSC, kits containing a pharmaceutical composition, and methods of preparing, propagating and using MDSCs or differentiated derivatives thereof The uses of these biological materials include methods of treating disorders or diseases, as well as methods of ameliorating a symptom associated with any such disorder or disease. | 2013-05-23 |
20130129697 | Enhanced Staphylolytic Activity of the Staphylococcus aureus Bacteriophage vB_SauS-philPLA88 Virion-Associated Peptidoglycan Hydrolase HydH5: Fusions, Deletions and Synergy with LysH5 - Virion-associated peptidoglycan hydrolases have a potential as antimicrobial agents due to their ability to lyse Gram positive bacteria on contact. Full-length HydH5, a virion-associated peptidoglycan hydrolase from the | 2013-05-23 |
20130129698 | CONJUGATED BLOOD COAGULATION FACTOR VIIA - The present invention provides a biocompatible polymer conjugated to FVIIa via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIIa, and pharmaceutical compositions comprising such conjugated forms of FVIIa. | 2013-05-23 |
20130129699 | BOTULINUM TOXIN COMPOSITIONS AND METHODS - Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a | 2013-05-23 |
20130129700 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE - The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD. | 2013-05-23 |
20130129701 | Methods and Compositions for Sequence Specific RNA Endonucleases - The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use. | 2013-05-23 |
20130129702 | MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF RNA VIRAL DISEASES - The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one catalytically active fragment thereof, such as the p40, p69, p100 subunits, to a patient in need thereof. The present inventors have determined that overexpression of 2-5AS causes a reduction in epithelial cell damage, reduction in infiltration of mononuclear cells in the peribronchiolar and perivascular regions, and reduction in thickening of the septa in the lungs. Levels of chemokines, such as MIP1-α, are also reduced upon overexpression of 2-5AS. The subject invention also pertains to pharmaceutical compositions containing a nucleotide sequence encoding 2-5 AS and a pharmaceutically acceptable carrier, as well as vectors for delivery of the 2-5 AS nucleotide sequence. | 2013-05-23 |
20130129703 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ISOLEUCYL TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-05-23 |
20130129704 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF THREONYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-05-23 |
20130129705 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF CYSTEINYL-tRNA SYNTHETASE - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-05-23 |
20130129706 | Crotoxin Administration for Cancer Treatment and Pain Relief - Disclosed is a method for treating cancer and/or pain using an intra-patient dose escalation procedure to deliver dosages of crotoxin. | 2013-05-23 |
20130129707 | ANTIMICROBIAL ACTIVITY ENHANCING AGENT - An antimicrobial activity enhancing agent for lactoferrin or a lactoferrin hydrolysate, which contains a milk protein as an active ingredient and has the following properties, and a method for producing the antimicrobial activity enhancing agent, which comprises (a) the step of contacting raw milk with a cation exchange resin to adsorb proteins in the raw milk to the cation exchange resin, (b) the step of washing the cation exchange resin having undergone the adsorption treatment, and flowing an elution solvent to elute a protein fraction having an isoelectric point of 9.0 to 11.0, and (c) the step of subjecting the eluted protein fraction to membrane filtration using an ultrafiltration membrane having a molecular weight cutoff of 30 kDa to prepare the milk protein having the following properties: | 2013-05-23 |
20130129708 | SELF-RENEWAL PROMOTER FOR NEURAL STEM CELLS AND METHOD FOR USING SAME - An object of the present invention to provide an agent for promoting the self-renewal of the neural stem cells and a method of using the same. ECF-L contained in a culture supernatant of endothelial progenitor cells derived from bone marrow has an effect of promoting the self-renewal of neural stem cells. Accordingly, ECF-L can be used as an ingredient of an agent for promoting the self-renewal of the neural stem cells, a pharmaceutical composition for growing the neural stem cells, and a pharmaceutical composition for treating a disease associated with neural dysfunction. | 2013-05-23 |
20130129709 | Fraction of Proteins and Peptides Derived from Egg White and Protein Derived From Egg White and Use Thereof as Anti Listeria Agent - The invention relates to a fraction of peptides and/or proteins that are derived from egg white and that are capable of binding heparin, for its anti- | 2013-05-23 |
20130129710 | HEMOSTATIC COMPOSITIONS - The invention discloses a method for producing a hemostatic composition comprising mixing a biocompatible polymer suitable for use in hemostasis and a genipin-type crosslinker, crosslinking said polymer by said genipin-type crosslinker to obtain a crosslinked biocompatible polymer, and finishing said crosslinks polymer to a pharmaceutically acceptable hemostatic composition, new hemostatic compositions and methods for using such compositions. | 2013-05-23 |
20130129711 | ANTI-ALLERGIC AGENT - Provided is an antiallergic agent including, as an active ingredient, a fermentation product of a propionic acid bacterium. Also provided is a method of using the antiallergic agent to prevent and/or improve skin roughness. | 2013-05-23 |
20130129712 | SELF-ASSEMBLING HYDROGELS BASED ON DICEPHALIC PEPTIDE AMPHIPHILES - We have disclosed dicephalic amphiphiles having peptide sequences as the head groups. We have also disclosed self-assembly hydrogels prepared from the dicephalic peptide amphiphiles. These hydrogels are useful for the encapsulation and delivery of bioactives to a patient. | 2013-05-23 |
20130129713 | METHOD OF ANTIGEN LOADING FOR IMMUNOTHERAPY - It is disclosed a method for obtaining a specific tumor antigen peptide repertoire loaded and/or activated dendritic cell comprising the steps of: a) exposing in suitable conditions a tumor cell expressing said specific tumor antigen peptide repertoire to at least one Pattern Recognition Receptor (PRR) agonist and/or to an inflammatory cytokine to obtain a tumor cell with an increased activity of at least one protein belonging to the group of connexins; b) co-culturing said tumor cell with an increased activity of at least one protein belonging to the group of connexins with dendritic cells, to get specific tumor antigen peptide repertoire loaded and/or activated dendritic cells; Step a) and b) are performed simultaneously or in sequence. The group of connexins preferably consists of connexin 43, connexin 40, connexin 45, connexin 47, connexin 50. | 2013-05-23 |
20130129714 | PREVENTION AND TREATMENT OF CAST NEPHROPATHY - Provided herein are polypeptides comprising or consisting essentially of a QSYDNTLSGSYVF (SEQ ID NO:1) or LSADSSGSYLYVF (SEQ ID NO:2) amino acid sequence. Also provided herein are methods of treating or preventing cast nephropathy in a subject. The methods comprise identifying a subject with or at risk of developing cast nephropathy and administering to the subject any of the polypeptides disclosed herein. | 2013-05-23 |
20130129715 | USE OF ANTI-PLAC1 PROTEIN ANTIBODIES AS BIOMARKERS OF INFERTILITY, DIAGNOSTIC KIT FOR THE DETECTION OF THE IMMUNE RESPONSE AGAINST PLAC1 AND USE OF PLAC1 PROTEIN IN THERAPEUTIC AND CONTRACEPTIVE FIELDS - Use of antibodies against PLAC1 protein as biomarkers of infertility, diagnostic kit for the detection of immune response against PLAC1 and use of PLAC1 protein in therapeutic and contraceptive fields | 2013-05-23 |
20130129716 | System and method for determining compatibility of bioactive agents and formulations provided therefrom - A method for determining compatibility of bioactive agents (i.e. supplement formulation components, pharmacological agents, etc.), comprising (i) determining compatibility by and between components contained in a supplement formulation, i.e. vitamins and/or minerals, (ii) determining compatibility by and between the formulation components and the body, and (iii) determining compatibility by and between the formulation components and pharmacological agents, i.e. prescribed and over-the-counter medications, and formulations derived therefrom. | 2013-05-23 |
20130129717 | Monoclonal Antibodies Against Extracellular Loops of C5aR - The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation. | 2013-05-23 |
20130129718 | PURIFICATION OF ANTI-C-MET ANTIBODIES - Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same. | 2013-05-23 |
20130129719 | HER2 NUCLEIC ACID APTAMERS - The present invention relates to optimized HER2 aptamers and methods of using these aptamers. | 2013-05-23 |
20130129720 | Combination Cancer Therapies with Wortmannin Analogs - Provided herein are combination therapies for the treatment of certain cancers in a subject by administering a combination of a therapeutic and a wortmannin analog to that subject. | 2013-05-23 |
20130129721 | Humanized Anti-C5aR Antibodies - The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor. | 2013-05-23 |
20130129722 | Methods for Treating Cancer by Administering an Anti-Ang-2 Antibody - The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis. | 2013-05-23 |
20130129723 | Heterodimer Binding Proteins and Uses Thereof - The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions. | 2013-05-23 |
20130129724 | DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS - The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions. | 2013-05-23 |
20130129725 | HUMAN FGF RECEPTOR AND BETA-KLOTHO BINDING PROTEINS - The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions. | 2013-05-23 |
20130129726 | PEPTIDE HAVING CELL MEMBRANE PENETRATING ACTIVITY - Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance. | 2013-05-23 |
20130129727 | METHODS AND SYSTEMS FOR INCREASING PROTEIN STABILITY - Methods and systems for increasing stability of a target polypeptide in a serum are described. The methods and systems utilize a fusion protein comprising a single-domain antibody against a serum albumin (SASA), the target polypeptide and optionally a linker. The fusion protein has a significantly prolonged serum half life in comparison with the target polypeptide alone. The SASA fusion tag also facilitates the expression and purification of the fusion protein. This allows direct in vivo screening or utilization of the target polypeptide for its biological activity or efficacy regardless of its intrinsic serum half life, which has significantly increased the number of candidates for the development of novel protein based diagnosis or treatment. | 2013-05-23 |
20130129728 | ANTIBODIES TO THE C3D FRAGMENT OF COMPLEMENT COMPONENT 3 - The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response. | 2013-05-23 |
20130129729 | COMPOSITIONS COMPRISING CROSS-SPECIES-SPECIFIC ANTIBODIES AND USES THEREOF - The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific antibodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases. | 2013-05-23 |
20130129730 | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule. | 2013-05-23 |
20130129731 | ANTI C-MET ANTIBODY AND USES THEREOF - An anti c-Met antibody or antigen-binding fragment thereof comprising a heavy-chain variable region having heavy-chain complementarity determining region (CDR) amino acid sequences of SEQ ID NOs: 1, 2 and 3, and a light-chain variable region having light-chain CDR amino acid sequences of SEQ ID NOs: 4, 5, and 6; and a method of wound healing, tissue regeneration, or cell proliferation comprising administration of same; as well as related compositions and methods. | 2013-05-23 |
20130129732 | METHOD FOR PRESERVING FOOD - Method for producing microbially stabilized foods characterized in that a food containing a dialkyl dicarbonate is treated by means of electroporation. | 2013-05-23 |
20130129733 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 2013-05-23 |
20130129734 | COMPOSITION AND METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LEUKEMIA - The present disclosure relates generally to compositions and methods for the diagnosis, prognosis and treatment of leukemia, in particular leukemia in which leukemic cells, or neoplastic precursors thereof, express Fat1 or a homolog of Fat1 that is substantially not expressed on normal blood cells. | 2013-05-23 |
20130129735 | ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE - The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies. | 2013-05-23 |
20130129736 | ASPP2 SPLICING VARIANT - The present invention relates to a method for the in vitro determination of the presence of or a predisposition of a patient to the development of cancer. In the method according to the invention, the presence of a marker is determined in a biological sample of the patient, said marker being selected from a) the amino acid sequence SEQ ID Nr. 2 from the sequence protocol that is provided, or b) a nucleic acid that encodes the amino acid sequence with the SEQ ID Nr. 2. The invention further relates to the amino acid and the encoding nucleic acid and to the use thereof in diagnostics and for molecular therapeutic approaches. | 2013-05-23 |
20130129737 | Group B Streptococcus Polypeptides Nucleic Acids and Therapeutic Compositions and Vaccines Thereof - This invention provides an isolated nucleic acid encoding a polypeptide comprising amino acid sequences of a streptococcal matrix adhesion E (EmaE) polypeptide. Antibodies to the EmaE polypeptide and immunogenic fragments thereof are also provided. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptide, antibodies thereto, and nucleic acids. | 2013-05-23 |
20130129738 | PHARMACEUTICAL COMPOSITION - Disclosed is an influenza virus infection inhibitor. Specifically disclosed is a pharmaceutical composition that is composed of an inhibitor such as an antibody which recognizes a peptide comprising the amino acid sequence of RERRRKKR (SEQ ID NO: 1) and inhibits the action of introducing an RR sequence into a cell. The influenza virus infection inhibitor is produced so as to contain the pharmaceutical composition. | 2013-05-23 |
20130129739 | NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE - The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling. | 2013-05-23 |
20130129740 | NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B - The invention provides proteins from group B | 2013-05-23 |
20130129741 | IDENTIFICATION AND MOLECULAR CHARACTERISATION OF PROTEINS, EXPRESSED IN THE IXODES RICINUS SALIVARY GLANDS - The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the | 2013-05-23 |
20130129742 | Human leukolectins and uses thereof - The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal. | 2013-05-23 |
20130129743 | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE - The invention provides anti-HtrA1 antibodies and methods of using the same. | 2013-05-23 |
20130129744 | PLASMINOGEN-ACTIVATING ANTIBODY, USE AND PRODUCING METHOD THEREOF AND AGENT INCLUDING THE SAME - An antibody for activating plasminogen is provided. The antibody is produced from a hybridoma cell line deposited on Nov. 24, 2011 under accession number BCRC 960433 at Food Industry Research and Development Institute, 331 Shih-Pin Road, Hsinchu 300, Taiwan. The uses and producing method of the antibody, and an agent including the antibody used for treating stroke, myocardial infarction or syndromes cause by thrombus are also disclosed. | 2013-05-23 |
20130129745 | ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use. | 2013-05-23 |
20130129746 | ANTI-SERUM ALBUMIN BINDING VARIANTS - The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts. | 2013-05-23 |
20130129747 | CROSS-PROTECTIVE PATHOGEN PROTECTION, METHODS AND COMPOSITIONS THEREOF - The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved sites that are not normally immunogenic for antibodies. Also disclosed herein are assays for detecting cross-protective antibodies, methods of generating novel cross-protective antibodies. Further provided are novel antibodies against influenza. | 2013-05-23 |
20130129748 | METHODS FOR IDENTIFYING POLYPEPTIDE TARGETS AND USES THEREOF FOR TREATING IMMUNOLOGICAL DISEASES - The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders. | 2013-05-23 |
20130129749 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 2013-05-23 |
20130129750 | PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 2013-05-23 |
20130129751 | METHOD FOR TREATING PROSTATITIS UTILIZING PORE-FORMING PROTEIN PROAEROLYSIN - The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins. | 2013-05-23 |
20130129752 | TARGETED DELIVERY TO LEUKOCYTES USING PROTEIN CARRIERS - Disclosed herein are is a leukocyte-selective delivery agent comprising, a targeting moiety that selectively binds LFA-I, a protein carrier moiety covalently linked to the targeting moiety, and a therapeutic agent associated with the carrier moiety. The delivery agent may be further selective for activated leukocytes, wherein the targeting moiety selectively binds LFA-I in its activated conformation. The targeting moiety comprises an antibody or functional fragment thereof, such as an scFV. Examples of antibodies or fragments thereof which selectively bind LFA-I activated conformation bind to the locked open I domain of LFA-I, or binds to the leg domain of the β2 subunit of LFA-I ((ILP2)—The antibody or functional fragment thereof may alternatively bind non-selectively to both low affinity and high affinity LFA-I. Examples of a non-protein carrier are a basic polypeptide such as protamine or a functional fragment thereof. One such fragment is RSQSRSRYYRQRQRSRRRRRRS. The therapeutic agent may comprise one or more of a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. An example of a nucleic acid delivery agent comprises an RNA interference molecule. Examples of RNA interference molecules are siRNA, dsRNA, StRNA, shRNA, miRNA, and combinations thereof. Specific siRNAs are provided. Other examples of a nucleic acid delivery agent are a small RNA, an antagomir, an LNA, and an antisense oligonucleotide. Methods for leukocyte-selective delivery, or activated leukocyte-selective delivery in vivo, in vitro and ex vivo are also provided. | 2013-05-23 |
20130129753 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF - The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer. | 2013-05-23 |
20130129754 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PROTEIN - The present application describes a coding nucleic acid sequence, particularly a messenger RNA (mRNA), comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. for the use in the treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or genetic diseases, or in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and an ex vivo and in vivo method. | 2013-05-23 |
20130129755 | METHOD OF PRODUCING RECOMBINANT PROTEINS WITH MANNOSE-TERMINATED N-GLYCANS - We describe a method of expressing a recombinant protein comprising mannose-terminated N-glycans from a host cell, the method comprising: (a) introducing a nucleic acid encoding a recombinant protein into a Chinese Hamster Ovary (CHO) cell comprising a mutation in the GnT 1 gene (GenBank Accession Number AF343963) leading to loss of GnT 1 function; and (c) expressing the recombinant protein from the host cell, in which the expressed recombinant protein comprises a mannose-terminated glycan structure, and in which the method does not include a step of introducing functional GnT-1 into the host cell. The method may be used for producing recombinant glucocerebrosidase with a mannose-terminated glycan structure, suitable for treatment or prevention of Gaucher's Disease. | 2013-05-23 |
20130129756 | NOVEL IMMUNOADJUVANT COMPOUNDS AND USES THEREOF - The present invention relates to a cyclic beta glucan compound for use as an immuno adjuvant and vaccine composition comprising thereof. These novel adjuvant compounds represent in particular a new class of dendritic cell activating molecules. | 2013-05-23 |
20130129757 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES - Psoralen compounds of Formula (I): | 2013-05-23 |
20130129758 | NOVEL CATIONIC AMPHIPHILES WITH MANNOSE-MIMICKING HEAD-GROUPS AND A PROCESS FOR THE PREPARATION THEREOF - The present invention discloses novel cationic amphiphiles containing mannose-mimicking shikimic and quinic acid head-groups and a process for preparing cationic amphiphiles with mannose-mimicking polar head-groups such as, shikimic and quinic acids. The findings described herein also demonstrate that compounds of the present invention can target model DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterpart in dendritic cell (DC, the most professional APC) based genetic immunization in mice. Cationic amphiphiles with mannose-mimicking quinic and shikimic acid head-groups described in the present invention are likely to find future applications in the field of genetic immunization. | 2013-05-23 |
20130129759 | PEPTIDE VACCINES FOR CANCERS EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES - The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines. | 2013-05-23 |
20130129760 | Polypeptides - A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer. | 2013-05-23 |
20130129761 | INFLUENZA VIRUS VACCINE AND USES THEREOF - Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use. | 2013-05-23 |
20130129762 | MARKER VACCINE FOR CLASSICAL SWINE FEVER - The invention relates to a marker vaccine for prophylactic treatment of classical swine fever comprising modified live attenuated classical swine fever virus. The viral amino acid sequence of the TAV-epitope of the E2 protein comprises a different sequence from that of a wild-type classical swine fever virus. The invention relates to pharmaceutical compositions of the marker vaccine. The invention also relates to a method of manufacturing marker vaccines for prevention of classical swine fever using selective antibody pressure. | 2013-05-23 |
20130129763 | INTERACTION OF MORAXELLA CATARRHALIS WITH EPITHELIAL CELLS, EXTRACELLULAR MATRIX PROTEINS AND THE COMPLEMENT SYSTEM - The present disclosure relates to surface proteins of | 2013-05-23 |
20130129764 | COMPOSITIONS AND METHODS TO DETECT VARIOUS INFECTIOUS ORGANISMS - The invention relates to compositions and methods for the detection of various infectious organisms, including heartworm ( | 2013-05-23 |
20130129765 | Compositions and Methods for Stimulating Immune Response Against Moraxella Catarrhalis - This invention provides a method for stimulating in an individual an immune response against | 2013-05-23 |
20130129766 | RECOMBINANT PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEINS 4 AND 5 AND THEIR USE - Accordingly, the invention provides constructs in which the nucleic acids encoding | 2013-05-23 |
20130129767 | VACCINES AGAINST PREGNANCY-ASSOCIATED MALARIA - The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women. | 2013-05-23 |
20130129768 | TREATMENT OR PREVENTION OF INFECTION - The invention relates to a method of reducing the incidence or severity of a disease or condition in a subject, said disease or condition being one associated with the presence of a microbial pathogen in an oral tissue of a subject, and including the use of a composition forming an anti-microbial and an immunogen against a microbial pathogen. | 2013-05-23 |
20130129769 | METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS DIRECTED TO SOLUBLE TARGETS - Provided herein are methods for making targeted therapeutics that target soluble agents such as toxins, venoms, and factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments the targeted therapeutics comprise a portion that interacts with a soluble agent of interest and a second portion that interacts with a subject's immune system, which enables treatment of a patient for exposure to the soluble agent. | 2013-05-23 |
20130129770 | INFLUENZA VACCINE - The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals. | 2013-05-23 |
20130129771 | REGULATORY IMMUNE CELLS WITH ENHANCED TARGETED CELL DEATH EFFECT - An isolated immune regulatory cell having an exogenous cell death-inducing moiety attached to a surface thereof is disclosed herein. Additionally, a molecule comprising a cell death-inducing moiety heterologously attached to an immune regulatory cell-specific binding moiety is disclosed herein. Methods of generating and using same as well as pharmaceutical compositions comprising same are also disclosed. | 2013-05-23 |
20130129772 | AMELIORATIVE OR PREVENTIVE EFFECT OF ANTRODIA CINNAMOMEA IN ARTHRITIS, CARTILAGE DESTRUCTION, OR CHONDROCYTE DEATH - The present invention relates to a method of preventing or ameliorating the symptoms of arthritis or preventing or ameliorating cartilage destruction or chondrocyte death in a subject suffered from arthritis, comprising administrating the subject an effective amount of an active component selected from a compound, a mixture, and a mycelium prepared from | 2013-05-23 |
20130129773 | ANTI-CANCER ACTIVE SUBSTANCE FROM ANTRODIA CAMPHORATA, METHOD FOR PREPARING THE SAME AND USE THEREOF - An anti-cancer active substance from | 2013-05-23 |
20130129774 | NOVEL XYLOGONE GANODERMOPHTHORA STRAIN WITH ANTIFUNGAL ACTIVITY, AND COMPOSITION INCLUDING SAME FOR PREVENTING PLANT DISEASES - A novel ascomycetous | 2013-05-23 |
20130129775 | OMEGA 7 RICH COMPOSITIONS AND METHODS OF ISOLATING OMEGA 7 FATTY ACIDS - Disclosed here are compositions rich in omega-7 fatty acids, including palmitoleic acid, and products rich in omega-7 fatty acids derived from algal biomass. The algae and/or compositions rich in omega-7 fatty acids may be used in products or as ingredients of products. Methods and systems for increasing the production or concentration of omega-7 fatty acids, and isolating omega-7 fatty acids from algal biomass are also disclosed herein. | 2013-05-23 |
20130129776 | Broad Spectrum Vaccine Against Typhoidal and Non-typhoidal Salmonella Disease - The present invention is drawn to multivalent | 2013-05-23 |
20130129777 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES - Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against | 2013-05-23 |
20130129778 | VIRAL PARTICLES DERIVED FROM AN ENVELOPED VIRUS - The invention relates to generating a vaccine based on immunogens from viral particles that initially have replication competency but are then inactivated by chemical, biophysical or other methods. The components of this vaccine may be a non-HIV enveloped virus that contains and expresses a gene related to the HIV Envelope gene such that the Envelope protein is expressed on the surface of viral particles. These viral particles may be further treated to reduce their replication competency. The vaccine further may contain components to improve its immunogenicity, tolerability, stability and ease of manufacture. | 2013-05-23 |
20130129779 | CATTLE REPRODUCTIVE DISEASE VACCINES - The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI | 2013-05-23 |
20130129780 | MODIFIED INFECTIOUS LARYNGOTRACHEITIS VIRUS (ILTV) AND USES THEREOF - Provided herein are modified infectious largotracheitis viruses (ILTVs) and methods of using the same. For example, provided are attenuated ILTVs. The attenuated ILTVs can be used to illicit immune responses in avian species. Optionally, the attenuated ILTVs can be used to vaccinate an avian subject or a population of avian subjects. Optionally, an attenuated ILTV is administered in ovo to an avian egg. One or more such in ovo administration can be used to increase the immunity of an avian herd. | 2013-05-23 |
20130129781 | METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY - Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery. | 2013-05-23 |
20130129782 | DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES - Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections. | 2013-05-23 |
20130129783 | USE OF BOTULINUM NEUROTOXIN TO ALLEVIATE VARIOUS DISORDERS - Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin. | 2013-05-23 |